Drug-induced autoimmune hepatitis: association with nitrofurantoin
DOI:
https://doi.org/10.32818/reccmi.a9n3a8Keywords:
Autoimmune hepatitis, Nitrofurantoin, Drug-induced autoimmune hepatitis, DILIAbstract
A 24-year-old female patient with a history of a urinary tract infection (UTI) treated with nitrofurantoin 3 weeks prior
subsequently developed jaundice, general malaise, and abdominal pain, leading her to seek emergency care. Laboratory
tests revealed elevated transaminases, and further studies showed positivity for antinuclear antibodies (ANA) and
anti-smooth muscle antibodies (ASMA). A liver biopsy demonstrated lymphocytic infiltration and interface hepatitis,
leading to a diagnosis of drug-induced autoimmune hepatitis secondary to nitrofurantoin. Treatment with corticosteroids
was initiated with a favorable evolution.
Downloads
Metrics
References
Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol. 2011; 55(1): 171-82.
doi: https://doi.org/10.1016/j.jhep.2010.12.012 (último acceso oct. 2024). DOI: https://doi.org/10.1016/j.jhep.2010.12.012
Tanaka A. Autoimmune Hepatitis: 2019 Update. Gut Liver. 2020; 14(4): 430-438.
doi: https://doi.org/10.5009/gnl19261 (último acceso oct. 2024). DOI: https://doi.org/10.5009/gnl19261
Ludz C, Stirnimann G, Semela D, Mertens J, Kremer AE, Sinnreich MF, et al. Epidemiology,
clinical features and management of autoimmune hepatitis in Switzerland:
a retrospective and prospective cohort study. Swiss Med Wkly. 2023; 153:
doi: https://doi.org/10.57187/smw.2023.40102 (último acceso oct. 2024). DOI: https://doi.org/10.57187/smw.2023.40102
Tan CK, Ho D, Wang LM, Kumar R. Drug-induced autoimmune hepatitis: a minireview.
World J Gastroenterol. 2022; 28(24): 2654-2666. doi: https://dx.doi. DOI: https://doi.org/10.3748/wjg.v28.i24.2654
org/10.3748/wjg.v28.i24.2654 (último acceso oct. 2024).
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis:
standard treatment and systematic review of alternative treatments. World J Gastroenterol. 2017; 23(33): 6030-6048. doi: https://doi.org/10.3748/wjg.v23.i33.6030 DOI: https://doi.org/10.3748/wjg.v23.i33.6030
(último acceso oct. 2024).
Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, et al. IAIHG and
EASL DHILI Consortium. Nomenclature, diagnosis and management of druginduced
autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report.
J Hepatol. 2023; 79(3): 853-866. doi: https://doi.org/10.1016/j.jhep.2023.04.033 DOI: https://doi.org/10.1016/j.jhep.2023.04.033
(último acceso oct. 2024).
García-Cortés M, Pinazo-Bandera JM, Lucena MI, Andrade RJ. Drug-induced autoimmune-
like hepatitis. Clin Liver Dis (Hoboken). 2024; 23(1): e0172. doi: https://
doi.org/10.1016/j.jhep.2023.04.033 (último acceso oct. 2024).
Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of autoimmune hepatitiscellular
and molecular mechanisms. Int J Mol Sci. 2021; 22(24): 13578. doi: https:// DOI: https://doi.org/10.3390/ijms222413578
doi.org/10.3390/ijms222413578 (último acceso oct. 2024).
Covelli C, Sacchi D, Sarcognato S, Cazzagon N, Grillo F, Baciorri F, Fanni D, Cacciatore
M, Maffeis V, Guido M. Pathology of autoimmune hepatitis. Pathologica. 2021;
(3): 185-193. doi: https://doi.org/10.32074/1591-951X-241 (último acceso oct. DOI: https://doi.org/10.32074/1591-951X-241
.
Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis.
United European Gastroenterol J. 2019;7(9): 1156-1163. doi: https://doi. DOI: https://doi.org/10.1177/2050640619872408
org/10.1177/2050640619872408 (último acceso oct. 2024).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Raúl Fabrizio Manchamé-Moreno, Christyan Arturo Borrayo-Alvarado
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
